Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review.
Fiche publication
Date publication
décembre 2022
Journal
Cardiovascular diabetology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LAGROST Laurent, Pr VERGES Bruno, Pr MASSON David
Tous les auteurs :
Rouland A, Masson D, Lagrost L, Vergès B, Gautier T, Bouillet B
Lien Pubmed
Résumé
Apolipoprotein C1 (apoC1) is a small size apolipoprotein whose exact role is not totally clarified but which seems to modulate significantly the metabolism of lipoproteins. ApoC1 is involved in the metabolism of triglyceride-rich lipoproteins by inhibiting the binding of very low density lipoproteins (VLDL) to VLDL-receptor (VLDL-R), to low density lipoprotein receptor (LDL-R) and to LDL receptor related protein (LRP), by reducing the activity of lipoprotein lipase (LPL) and by stimulating VLDL production, all these effects leading to increase plasma triglycerides. ApoC1 takes also part in the metabolism of high density lipoproteins (HDL) by inhibiting Cholesterol Ester Transfer Protein (CETP). The functionality of apoC1 on CETP activity is impaired in diabetes that might account, at least in part, for the increased plasma CETP activity observed in patients with diabetes. Its different effects on lipoprotein metabolism with a possible role in the modulation of inflammation makes the net impact of apoC1 on cardiometabolic risk difficult to figure out and apoC1 might be considered as pro-atherogenic or anti-atherogenic depending on the overall metabolic context. Making the link between total plasma apoC1 levels and the risk of cardio-metabolic diseases is difficult due to the high exchangeability of this small protein whose biological effects might depend essentially on its association with VLDL or HDL. The role of apoC1 in humans is not entirely elucidated and further studies are needed to determine its precise role in lipid metabolism and its possible pleiotropic effects on inflammation and vascular wall biology. In this review, we will present data on apoC1 structure and distribution among lipoproteins, on the effects of apoC1 on VLDL metabolism and HDL metabolism and we will discuss the possible links between apoC1, atherosclerosis and diabetes.
Mots clés
Apolipoprotein C1, Atherosclerosis, Cholesteryl ester transfer protein, Diabetes, High density lipoproteins, Lipoprotein metabolism, Triglyceride-rich lipoproteins
Référence
Cardiovasc Diabetol. 2022 12 5;21(1):272